AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 293: F193-F199, 2007. First published March 27, 2007; doi:10.1152/ajprenal.00022.2007
0363-6127/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Table
Right arrow All Versions of this Article:
293/1/F193    most recent
00022.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keck, M.
Right arrow Articles by Brooks, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keck, M.
Right arrow Articles by Brooks, H. L.

Hormonal status affects the progression of STZ-induced diabetes and diabetic renal damage in the VCD mouse model of menopause

Maggie Keck, Melissa J. Romero-Aleshire, Qi Cai, Patricia B. Hoyer, and Heddwen L. Brooks

Department of Physiology, College of Medicine, University of Arizona, Tucson, Arizona

Submitted 12 January 2007 ; accepted in final form 16 March 2007


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Changes in the estrogen/testosterone balance at menopause may negatively influence the development of diabetic kidney disease. Furthermore, recent studies suggest that changes in hormone levels during perimenopause may influence disease development. Injection of 4-vinylcyclohexene diepoxide (VCD) in B6C3F1 mice induces gradual ovarian failure, preserving both the perimenopausal (peri-ovarian failure) and menopausal (post-ovarian failure) periods. To address the impact of the transition into menopause on the development of diabetes and diabetic kidney damage, we used streptozotocin (STZ)-induced diabetes in the VCD model of menopause. After 6 wk of STZ-induced diabetes, blood glucose was significantly increased in post-ovarian failure (post-OF) diabetic mice compared with cycling diabetic mice. In peri-ovarian failure (peri-OF) diabetic mice, blood glucose levels trended higher but were not significantly different from cycling diabetic mice, suggesting a continuum of worsening blood glucose across the menopausal transition. Cell proliferation, an early marker of damage in the kidney, was increased in post-OF diabetic mice compared with cycling diabetic mice, as measured by PCNA immunohistochemistry. In post-OF diabetic mice, mRNA abundance of early growth response-1 (Egr-1), collagen-4{alpha}1, and matrix metalloproteinase-9 were increased and 3beta-hydroxysteroid dehydrogenase 4 (3beta-HSD4) and transforming growth factor-beta2 (TGF-beta2) were decreased compared with cycling diabetic mice. In peri-OF diabetic mice, mRNA abundance of Egr-1 and 3beta-HSD4 were increased, and TGF-beta2 was decreased compared with cycling diabetic mice. This study highlights the importance and utility of the VCD model of menopause, as it provides a physiologically relevant system for determining the impact of the menopausal transition on diabetes and diabetic kidney damage.

diabetes; 3beta-HSD4; perimenopause; real-time PCR; estrogen

DIABETES IS ONE OF THE MOST prevalent and costly diseases afflicting developed countries, with estimates placing the current global cost of diabetes at $150 billion a year (1). Approximately one-third of all diabetics die of end-stage renal disease (33) due to progressive renal damage and hypertension.

17beta-Estradiol is considered protective against the development and progression of many diseases, including cardiovascular (9) and renal disease (34). Premenopausal women have slower rates of progression of nondiabetic renal disease than age-matched men (23), a difference that seems to disappear after menopause (3). The impact of estrogen on diabetic renal disease is less clear, however. Several studies demonstrate a decreased incidence of diabetic renal disease in women, but others have found no difference between men and women (34).

The 5–10 years preceding menopause is termed perimenopause, and during this time estrogen levels fluctuate, with periods of low estrogen interspersed with periods of very high estrogen (31). The periods of low estrogen become more frequent as a woman approaches menopause until circulating levels of 17beta-estradiol drop to continuously very low levels at menopause (31). Following menopause the ovaries secrete androgens (36), although their contribution to the overall hormonal state of the body is debated (4). Recent studies find that some risk factors for estrogen-influenced diseases begin to develop during perimenopause (7, 19). This suggests that study of the perimenopausal period may lead to new understanding of and preventive therapies for estrogen-influenced diseases (37).

The most commonly used animal model of menopause is surgical removal of the ovaries (ovariectomy). With this model there is no period analogous to perimenopause, and any postmenopausal androgen secretion by the ovaries is lost. High androgen levels have been implicated in the development of renal disease (22, 28), thus the lack of postmenopausal ovaries in the ovariectomy model of menopause, combined with the lack of a perimenopausal period, limits the study of diabetic kidney disease across the menopausal transition.

Here, a new chemical model of menopause, in which repeated daily injections of 4-vinylcyclohexene diepoxide (VCD) induce gradual ovarian failure in mice (13), was used. In this model, the period preceding full ovarian failure mimics the perimenopausal period (termed peri-ovarian failure in this study): cycles gradually become longer and more irregular, estrogen levels decrease, and follicle-stimulating hormone levels increase. Following ovarian failure (termed post-ovarian failure in this study) the ovaries secrete androgens (20), similar to postmenopausal human ovaries. This model provides a new and unique opportunity to study the development and progression of diabetic kidney disease across the menopausal transition.

In this study, the VCD model of menopause was combined with the streptozotocin (STZ) model of type 1 diabetes. STZ-induced diabetes was begun during the period analogous to perimenopause in humans (i.e., during peri-ovarian failure) or during the period analogous to postmenopause in humans (i.e., post-ovarian failure). We hypothesized that changes in hormone levels across the menopausal transition would negatively affect the development of diabetes and diabetic kidney damage. The data presented here support this hypothesis and further suggest that the perimenopausal period may be important in the development and progression of diabetic renal disease. This study highlights the utility of the VCD mouse model of menopause in the study of diabetic renal disease across the menopausal transition.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. Twenty-eight-day-old female B6C3F1 mice were used in this study. Animals were housed in standard cages in the animal facility of the Arizona Health Sciences Center under National Institutes of Health guidelines and had ad libitum access to regular food and water. All protocols were approved by the Institutional Animal Care and Use Committee at the University of Arizona.

Induction of ovarian failure. VCD (Sigma, V3630) was administered via intraperitoneal injection at a dose of 160 mg/kg body wt using a dosing standard of 2.5 ml/kg body wt for 15 consecutive days to induce gradual ovarian failure (13, 20). Sesame oil was used as vehicle control. Progression into ovarian failure was monitored by daily vaginal cytology. Ten consecutive days of diestrus were considered indicative of ovarian failure (13).

Induction of diabetes. Diabetes was induced by intraperitoneal injection of STZ (Sigma, S0130) at a dose of 75 mg/kg body wt using a dosing standard of 0.2 ml/22 g body wt to 4-h fasted mice for 3 consecutive days. Mice were separated into two study groups: in the first group, STZ was administered during peri-ovarian failure, 3 days after the end of VCD dosing (Fig. 1 : Perimenopausal Study). In the second group, STZ was administered post-ovarian failure, 2 wk after a mouse entered ovarian failure (Fig. 1: Menopausal Study). In both studies, cycling mice (not VCD-injected) were injected with STZ on the same day. Citrate buffer was used as vehicle control. Urine glucose was monitored as an indication of the onset of diabetes using standard urine glucose test strips (VWR, 44561-110). Animals were weighed regularly and visually monitored for signs of ill health. Mice were killed 6 wk after STZ injection. Mice were fasted for 4 h before death, at which point blood was collected, and blood glucose was measured using the CardioCheck PA Blood Testing Device (HealthCheck Systems, 2568) with CardioCheck Glucose Test Strips (HealthCheck Systems, 2556).


Figure 1
View larger version (12K):
[in this window]
[in a new window]

  		Fig. 1. Timeline of experimental study groups. Twenty-eight-day-old female B6C3F1 mice were separated into 2 study groups and given intraperitoneal injections of 4-vinylcyclohexene diepoxide (VCD) and streptozotocin (STZ) to induce gradual ovarian failure and diabetes, respectively. All mice were dosed with VCD for 15 consecutive days and with STZ for 3 consecutive days. Large up arrows indicate the initial day of dosing of VCD or STZ. Death followed 6 wk after STZ dosing in both studies.

 
RNA isolation. Kidneys were separated into cortex and medulla, and RNA was isolated from renal cortex using the Qiagen RNeasy Mini Kit (74104) according to the manufacturer's protocol for isolation from tissue. DNA contamination was eliminated during the isolation procedure with a 15-min DNAse incubation (Qiagen, 79254). RNA was quantified using a Nanodrop ND1000 spectrophotometer (Wilmington, DE).

Real-time PCR. Real-time PCR was performed as previously described (21). Briefly, 2.5 µg of RNA were reverse transcribed with the MLV-Reverse Transcriptase enzyme (Invitrogen, 28025013), and the resulting cDNA was diluted 1:25 to an approximate final concentration of 8 ng/µl. Each real-time PCR reaction contained 5 µl SYBR Green master mix (Stratagene, 600581), 1 µl water, 2 µl diluted cDNA, and 5 pmol each of forward and reverse primer in a total volume of 10 µl. Each reaction was performed in triplicate at 95°C for 5 min and then 95°C for 15 s and 60°C for 30 s for 40 cycles. The RotorGene RG3000 (Corbett Research, San Francisco, CA) sequence detection system was used. Primers were designed to the 3' end of genes of interest using the Primer3 software (30) and are listed in supplemental data A (the online version of this article contains supplemental data). Ct values were used to calculate the expression levels of genes of interest relative to the expression of beta-actin mRNA, measured in parallel samples. Analysis was performed as described (11), and results are presented as mean fold change on a base 2 logarithmic scale.

Immunohistochemistry. Kidneys were fixed in 4% paraformaldehyde overnight, embedded in paraffin, and sectioned (4 µm) by the University of Arizona Pathology Laboratory. Sections were deparaffinized with xylene and rehydrated in graded ethanol. Endogenous horseradish peroxidase activity was blocked with 0.3% H2O2 in methanol for 30 min. Antigen retrieval was performed by boiling sections in 10 mM citrate buffer for 10 min. Nonspecific binding was blocked with 5% goat serum in 1% BSA with 0.05% Tween 20. Sections were incubated at 4°C overnight in antiproliferating cell nuclear antigen (PCNA; 1:100 dilution; Santa Cruz Biotechnology, SC-25280), followed by biotinylated secondary antibody (1:200 dilution; Zymed, 81-6740) for 30 min at 37°C and horseradish peroxidase-conjugated streptavidin (1:200 dilution; Zymed, 43-4323) for 30 min at 37°C. Labeling was visualized with chromogen diaminobenzidine (Zymed, 00-2014), and sections were counterstained with hematoxylin (Zymed, 00-8011). Coverslips were mounted with Permount mounting solution (Fisher, SP15-100). Positively stained nuclei were counted as a proportion of total nuclei within each of five nonoverlapping fields of view for each section. Each field of view contained ~200 cells.

Statistics. Data were analyzed using Student's t-test or one-way ANOVA followed by Student-Newman-Keuls post hoc test to identify differences between groups. In all tests, P < 0.05 was considered significant. Results are presented as mean ± SD or SE.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Initiation of menopause. To study the effect of menopause on the development of diabetes and diabetic kidney damage, we combined the STZ model of type 1 diabetes with the VCD model of menopause in B6C3F1 female mice (20). Repeated injections of VCD induce gradual ovarian failure in mice, which is analogous to menopause in humans. In this study, diabetes was induced using STZ 2 wk after a mouse entered ovarian failure, as shown in Fig. 1. An age-matched cycling mouse (not VCD-injected) was injected with STZ at the same time (Table 1). Mice were killed 6 wk after STZ dosing. Age-matched nondiabetic post-ovarian failure (post-OF) and nondiabetic cycling mice were killed as controls (see Table 1).


View this table:
[in this window]
[in a new window]

  		Table 1. Description of mouse groups

 
Blood glucose in post-ovarian failure diabetic mice. There was a significant increase in blood glucose in all STZ-injected mice compared with control mice (Fig. 2). Furthermore, glucose levels in post-OF diabetic mice were significantly higher than in cycling diabetic mice (336 ± 86 vs. 218 ± 76 mg/dl, P < 0.05). There was no significant difference in glucose levels between nondiabetic post-OF mice and cycling control mice (91 ± 23 vs. 79 ± 20, P > 0.05).


Figure 2
View larger version (12K):
[in this window]
[in a new window]

  		Fig. 2. Blood glucose measurements in post-ovarian failure diabetic mice. Cycling or post-ovarian failure mice were injected with STZ to induce diabetes. Fasted blood glucose levels were measured 6 wk after STZ treatment. Results are expressed as mean ± SD. Significant difference determined by Student-Newman-Keuls post hoc test following 1-way ANOVA. OF, ovarian failure. See Table 1 for n in each group.

 
PCNA immunohistochemistry. Cell proliferation is used as an early indicator of cell stress/damage in the kidney and occurs in the renal glomeruli and tubules in diabetic mice (14, 24, 38). PCNA is a DNA polymerase-associated protein expressed in proliferating cells (39). Immunohistochemistry was performed on kidney tissue sections using an antibody against PCNA. Representative sections of PCNA immunohistochemistry are shown in Fig. 3 A. There were significantly more PCNA-positive cells in the renal cortex of diabetic mice compared with nondiabetic mice (Fig. 3B). In addition, there was a further significant increase in PCNA-positive cells in the cortex of post-OF diabetic mice compared with cycling diabetic mice. PCNA staining was primarily in tubular not glomerular cells and was not seen in the medulla of any treatment group.


Figure 3
View larger version (84K):
[in this window]
[in a new window]

  		Fig. 3. Effect of diabetes and hormonal status on renal cortex cell proliferation. A: Representative sections from kidney cortex demonstrating PCNA staining (in red); nuclear counterstain with hemotoxylin (blue). a: Control. b: Post-OF. c: Diabetic. d: Post-OF/Diabetic. Magnification x400. B: graph presenting the mean PCNA-positive nuclei as a percentage of total nuclei. PCNA-positive nuclei and total nuclei were counted in 5 nonoverlapping fields of view for each section, with 3 animals in each treatment group. Results are presented as mean ± SD. Significant difference determined by Student Newman-Keuls post hoc test following 1-way ANOVA.

 
Real-time PCR in post-ovarian failure diabetic mice. In the kidney the expression of many genes associated with damage, such as collagen 4 and transforming growth factor-beta, is altered in response to diabetes (32). Thus real-time PCR was performed to determine whether the expression of genes associated with diabetic kidney damage was different depending on hormonal status. Several genes which were differentially expressed in the renal cortex of post-OF diabetic mice compared with cycling diabetic mice were identified. Three main patterns of changes in gene expression emerged, as shown in Fig. 4. Pattern 1: A significant change (increase or decrease) in mRNA abundance in post-OF diabetic mice compared with control mice and cycling diabetic mice, with no change between cycling diabetic and control mice (Fig. 4A). The expression of early growth response 1 (Egr-1), collagen 4{alpha}1 (Col4{alpha}1), and matrix metalloproteinase 9 (MMP9) fit this pattern. Egr-1 mRNA abundance was increased 2.87-fold (P < 0.05) in the cortex of post-OF diabetic mice compared with cycling diabetic and control mice. Col4{alpha}1 mRNA abundance was decreased 1.75-fold (P < 0.05) in post-OF diabetic mice compared with cycling diabetic and control mice. MMP9 mRNA abundance was decreased 1.89-fold (P < 0.05) in post-OF diabetic mice compared with cycling diabetic and control mice. There were no significant differences in mRNA abundance of any of these genes between cycling diabetic and control mice. Pattern 2: A significant decrease in mRNA abundance in cycling diabetic mice compared with control mice and a further significant decrease in post-OF diabetic mice (Fig. 4B). mRNA abundance of 3beta-hydroxysteroid dehydrogenase 4 (3beta-HSD4) fit this pattern, with a 1.39-fold decrease (P < 0.05) in cycling diabetic mice compared with control mice, and a further 1.30-fold decrease (P < 0.05) in post-OF diabetic mice compared with cycling diabetic mice. The mRNA abundance of 3beta-HSD4 in post-OF diabetic mice was decreased 1.79-fold (P < 0.05) compared with control mice. Pattern 3: A significant change in mRNA abundance in cycling diabetic mice compared with control mice, and a significant change in the opposite direction between post-OF and cycling diabetic mice such that there was no significant difference between post-OF diabetic and control mice (Fig. 4C). Transforming growth factor-beta2 (TGF-beta2) fit this pattern; the mRNA abundance of TGF-beta2 increased 1.60-fold (P < 0.05) in cycling diabetic mice compared with control mice and decreased 1.59-fold (P < 0.05) in post-OF diabetic mice relative to cycling diabetic mice. There was no significant difference in mRNA abundance of TGF-beta2 between post-OF diabetic and control mice. In addition, real-time PCR analysis was performed for the following genes: collagen 1{alpha}2, collagen 4{alpha}2, estrogen receptor {alpha}, fibronectin 1, PCNA, TGF-beta1, and TGF-beta3. No significant differences in renal cortex mRNA abundance between post-OF diabetic mice and cycling diabetic mice were found. For all of the above genes, there were no significant differences in the mRNA abundance between control and nondiabetic post-OF mice.


Figure 4
View larger version (14K):
[in this window]
[in a new window]

  		Fig. 4. Patterns of changes in mRNA abundance of genes associated with diabetic kidney damage. SYBR Green I real-time PCR measurements were used to derive Ct values for calculation of mRNA abundance. The data shown are mean relative gene expression normalized to control group ± SE. Assays for beta-actin were run in parallel on each sample for internal controls. Assays were run in triplicate on cDNA synthesized by reverse transcription from RNA samples. Significant difference determined by Student's t-test, n = 3 for each group. A: early growth response-1 (Egr-1). B: 3beta-hydroxysteroid dehydrogenase (3beta-HSD4). C: transforming growth factor-beta2 (TGF-beta2).

 
Menopause induced weight gain in nondiabetic mice. All mice gained weight throughout the study. Compared with control mice, post-OF nondiabetic mice rapidly gained weight following ovarian failure. Eight weeks post-ovarian failure, post-OF mice weighed significantly more than control mice (Fig. 5). There were no significant differences in weight between any of the other groups of mice.


Figure 5
View larger version (15K):
[in this window]
[in a new window]

  		Fig. 5. Weight gain in nondiabetic post-ovarian failure mice. Nondiabetic VCD-dosed mice (i.e., post-ovarian failure mice) weighed the same as control cycling mice until 2 wk after ovarian failure, at which point post-OF mice rapidly gained weight. Results are presented as mean ± SD. *P < 0.05 as determined by Student's t-test (n = 9 vs. 9).

 
Initiation of perimenopause. One of the strengths of the VCD model of menopause is that full ovarian failure is preceded by a period of irregular cycling, analogous to perimenopause in human women (13, 20). Thus, in a complementary study diabetes was induced during peri-ovarian failure (see Fig. 1: Perimenopausal Study); STZ dosing began 3 days after the end of VCD dosing. In contrast to the menopausal study, there was no difference in weight between any of the groups of mice at the end of the study.

Blood glucose in peri-ovarian failure diabetic mice. There was a significant increase in blood glucose in all STZ-injected mice compared with control mice (Fig. 6). Glucose levels in peri-OF diabetic mice trended higher but were not significantly different from cycling diabetic mice (238 ± 102 vs. 201 ± 96 mg/dl, P = 0.21). Compared with the menopausal study, glucose levels in peri-OF diabetic mice were significantly different from glucose levels in post-OF diabetic mice (238 ± 102 vs. 336 ± 86 mg/dl, P < 0.05).


Figure 6
View larger version (16K):
[in this window]
[in a new window]

  		Fig. 6. Blood glucose measurements in peri-ovarian failure diabetic mice. Mice were injected with STZ to induce diabetes, and fasted blood glucose was measured 6 wk after STZ treatment. Results are expressed as mean ± SD. Significant difference determined by Student-Newman-Keuls post hoc test following 1-way ANOVA. Filled bars, perimenopausal study; open bars, menopausal study. Data from menopausal study (Fig. 2) is shown for comparison. NS, nonsignificant.

 
Real-time PCR in peri-ovarian failure diabetic mice. Real-time PCR was performed comparing renal cortex mRNA abundance from peri-OF diabetic mice to cycling diabetic mice. Primers for genes whose expression was significantly different between post-OF diabetic and cycling diabetic mice (i.e., Egr-1, Col4{alpha}1, MMP9, 3beta-HSD4, and TGF-beta2) were used. As observed in the menopausal study, Egr-1 mRNA abundance was increased in peri-OF diabetic mice compared with cycling diabetic mice (increase of 2.05-fold, P < 0.05). TGF-beta2 was decreased in peri-OF diabetic mice compared with cycling diabetic mice (decrease of 1.6-fold, P < 0.05). In contrast to what was observed in post-OF diabetic mice, 3beta-HSD4 was increased in peri-OF diabetic mice compared with cycling diabetic mice (increase of 1.2-fold, P < 0.05), whereas in the post-OF diabetic mice 3beta-HSD4 was decreased compared with cycling diabetic mice.


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
VCD is a chemical by-product of rubber manufacturing which has been demonstrated to selectively destroy primordial and primary follicles in ovaries of rats and mice (reviewed in Ref. 8) without producing effects in large follicles or other tissues (20). We recently described the novel use of VCD as a means to induce gradual ovarian failure in mice (12). Ovarian failure in rodents is analogous to menopause in humans; thus VCD-treated mice serve as a new model of human menopause. Unlike previous rodent models of menopause, the VCD model preserves the period of irregular cycling and fluctuating hormone levels which precedes ovarian failure, termed perimenopause in humans (13). Also, following ovarian failure in the VCD model, the follicle-deplete ovaries secrete androgens, similar to the ovaries of postmenopausal humans (20).

Post-ovarian failure diabetic mice. In this study, we combined the VCD model of menopause with STZ-induced type 1 diabetes. Two groups of mice were studied: one in which diabetes was induced during impending ovarian failure (perimenopause), and one in which diabetes was induced post-ovarian failure (menopause). Following the induction of diabetes blood glucose levels were significantly higher in post-ovarian failure diabetic mice than in cycling diabetic mice. Post-ovarian failure mice also had higher blood glucose than mice in which diabetes was induced during impending ovarian failure (peri-ovarian failure).

STZ causes diabetes by destroying insulin-producing pancreatic beta-cells via oxidative stress-induced apoptosis. Recent data suggest that the presence of estrogen may protect beta-cells from STZ-induced oxidative stress. In a study in which STZ was used to induce diabetes in ovariectomized rats, estradiol-treated ovariectomized rats had significantly lower blood glucose than those untreated with estradiol. The authors speculated that estrogen may attenuate STZ-induced destruction of pancreatic beta-cells by decreasing inflammation (29) and thus may contribute to lower blood glucose levels in estrogen-treated rats. More recently, an in vitro study using STZ on primary cultures of pancreatic beta-cells demonstrated that estrogen protects beta-cells from oxidative stress-induced apoptosis (10).

Data from human studies suggest that estrogen also exerts a protective effect on pancreatic beta-cells in humans. In the Women's Health Initiative Hormone Trial, the incidence of newly diagnosed cases of diabetes was lower in women on hormone replacement therapy than in placebo-treated women (17). In perimenopausal women, longer cycle length (i.e., lower estrogen levels) has also been associated with higher blood glucose levels and hyperinsulinemia (19). Furthermore, in diabetic postmenopausal women, treatment with hormone replacement therapy improved insulin resistance (17).

Cell proliferation in post-ovarian failure diabetic mice. Renal cell proliferation and hypertrophy are early complications of diabetes (14, 24, 38); therefore, expression of PCNA can be used as a marker of early kidney damage. In our study, expression of PCNA was increased in kidneys from post-ovarian failure diabetic mice compared with cycling diabetic mice. These data suggest that renal damage develops more rapidly and/or severely in post-ovarian failure diabetic mice compared with cycling diabetic mice.

Low estrogen levels increase susceptibility to nephropathy (5), thus the loss of estrogen in post-ovarian failure diabetic mice may have contributed to the increased proliferation observed in this study. However, high circulating blood glucose has been positively correlated with an increase in diabetic nephropathy in mice (6), thus the higher levels of glucose we observed in post-ovarian failure diabetic mice could have contributed to the increased cell proliferation in our study.

Changes in gene expression in post-ovarian failure diabetic mice. Diabetic kidney damage is usually associated with the increased accumulation of extracellular matrix proteins, such as collagen and fibronectin. This increase is thought to be stimulated by increased expression of TGF-beta and the decreased expression and activity of matrix metalloproteinases (16, 32, 40). This study identified several genes which were differentially expressed in the renal cortex of post-ovarian failure diabetic mice and cycling diabetic mice. For example, in the renal cortex of post-ovarian failure diabetic mice, MMP9 expression was decreased compared with cycling diabetic mice. This result correlates well with previous in vivo studies in which MMP9 protein expression and activity level were decreased in ovariectomized diabetic rats (16) and in ovariectomized Dahl salt-sensitive rats (18). Previous in vitro studies in mesangial cells have found that estrogen increases the expression of MMP9 (26); thus the loss of estrogen in our model of menopause may explain the observed decrease in MMP9 mRNA expression.

We observed a decrease in mRNA abundance of collagen 4{alpha}1 and TGF-beta2 in post-ovarian failure diabetic kidneys compared with cycling diabetic kidneys. These data diverge from studies in which ovariectomy was associated with increased expression of TGF-beta and collagen 4 in diabetic rats (15, 16).

mRNA abundance of 3beta-HSD4 was significantly lower in the renal cortex of post-ovarian failure diabetic mice than in cycling diabetic mice. Murine 3beta-HSD4 is a 3-ketosteroid reductase which metabolizes progesterone and dihydrotestosterone to their inactive forms (2, 27). Recent studies identified 3beta-HSD4 expression as predictive of the degree to which glomerulosclerosis develops in the diabetic kidney, with lower expression of 3beta-HSD4 correlating with more severe glomerulosclerosis (35). A decrease in 3beta-HSD4 expression could lead to an increase in dihydrotestosterone levels. Dihydrotestosterone has been demonstrated to cause an increase in cell proliferation in a proximal tubule cell line (25); thus decreased 3beta-HSD4 expression could result in increased proliferation of proximal tubule cells. Our results are consistent with this hypothesis as we found both a decrease in 3beta-HSD4 mRNA abundance and an increase in cell proliferation in kidneys from post-ovarian failure diabetic mice compared with cycling diabetic mice and control mice.

Peri-ovarian failure diabetic mice. The VCD model of menopause is unique among rodent menopause models in that it retains residual ovarian tissue after ovarian failure and mimics the perimenopausal period. Recent studies find that changes in disease risk factors begin during perimenopause (7, 19) suggesting that the perimenopausal period may be critical in the development and prevention of estrogen-influenced diseases (37).

Data reported here found a trend toward increased glucose levels in peri-ovarian failure diabetic mice and a significant difference in blood glucose between post-ovarian failure diabetic mice and cycling diabetic mice. These data suggest a continuing trend of increasing blood glucose throughout the menopausal transition as estrogen gradually decreases.

Real-time PCR data from this study suggest that declining estrogen levels during peri-ovarian failure affect the expression of genes implicated in the development of diabetic kidney disease. For example, mRNA abundance of TGF-beta2 was lower in peri-ovarian failure diabetic mice than in cycling diabetic mice. This is similar to the decrease in mRNA abundance for this gene observed between post-ovarian failure diabetic mice and cycling diabetic mice. These data highlight the importance of the VCD model of perimenopause and menopause, as these changes in gene expression may be important in understanding disease progression and have implications for disease prevention and treatment.

In conclusion, this study suggests that estrogen may play an important role in protecting the kidney from diabetes-induced cell proliferation and disease. It is possible that not all of the differences we observed between post-ovarian failure diabetic mice and cycling diabetic mice are due to changes in estrogen levels. The increase in blood glucose levels in post-ovarian failure diabetic mice may account for some of the differences in gene expression and cell proliferation we observed. Also, preliminary evidence suggests androgens negatively affect the development of kidney disease (22, 28). The VCD model of menopause preserves the androgen-producing function of the post-ovarian failure ovaries (20); thus some of the differences we observed between post-ovarian failure diabetic mice and cycling diabetic mice may be due to differences in androgen levels or differences in the estrogen/androgen ratio as opposed to direct actions of estrogen alone.

As more women develop diabetes at younger ages, the number of women with diabetes at the time of the menopausal transition will increase, as will the number of postmenopausal women with diabetes. Here, we introduce a new model for studying the impact of the menopausal transition on the development of diabetic kidney disease. We show that blood glucose levels are increased in post-ovarian failure diabetic mice compared with cycling diabetic mice and that there are differences in the mRNA abundance of genes associated with diabetic kidney disease in post-ovarian failure diabetic mice compared with cycling diabetic mice. Furthermore, we show there is increased cell proliferation in post-ovarian failure diabetic mice compared with cycling diabetic mice. Finally, we present data which suggest the importance of studying the development of diabetic kidney disease in the context of the perimenopausal period. Together, these data highlight the importance and utility of the VCD model of menopause, as it provides a physiologically relevant system for determining the impact of diabetes on the kidney during the menopausal transition.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was funded by National Institutes of Health Grant AG-021948 to P. B. Hoyer, and M. Keck is supported by an NSF-IGERT Fellowship in Genomics, University of Arizona and The ARCS Foundation, Phoenix, AZ chapter.


   ACKNOWLEDGMENTS
 
We gratefully acknowledge Dr. R. Egleton for the use of the glucometer and for helpful advice and P. Christian for technical assistance.


   FOOTNOTES
 

Address for reprint requests and other correspondence: H. Brooks, Dept. of Physiology, College of Medicine, 1501 N Campbell Ave, Univ. of Arizona, Tucson, AZ 85724-5051 (e-mail: brooksh{at}email.arizona.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int 67: s14–s18, 2005.
  2. Clarke TR, Bain PA, Greco TL, Payne AH. A novel mouse kidney 3 beta-hydroxysteroid dehydrogenase complementary DNA encodes a 3-ketosteroid reductase instead of a 3 beta- hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase. Mol Endocrinol 7: 1569–1578, 1993.[Abstract]
  3. Coggins C, Lewis J, Caggiula A, Castaldo L, Klahr S, Wang S, Beck G. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 13: 1430–1437, 1998.[Abstract/Free Full Text]
  4. Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 86: 5060–5066, 2001.[Abstract/Free Full Text]
  5. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, Striker GE, Striker LJ. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 162: 1441–1448, 2003.[Abstract/Free Full Text]
  6. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 290: F214–F222, 2006.[Abstract/Free Full Text]
  7. Hinojosa-Laborde C, Craig T, Zheng W, Ji H, Haywood JR, Sandberg K. Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats. Hypertension 44: 405–409, 2004.[Abstract/Free Full Text]
  8. Hoyer PB, Sipes IG. Assessment of follicle destruction in chemical-induced ovarian toxicity. Annu Rev Pharmacol Toxicol 36: 307–331, 1996.[CrossRef][ISI][Medline]
  9. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85: 447–452, 1976.[ISI][Medline]
  10. Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, Mauvais-Jarvis F. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103: 9232–9237, 2006.[Abstract/Free Full Text]
  11. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-{delta}{delta}CT Method. Methods 25: 402–408, 2001.[CrossRef][ISI][Medline]
  12. Lohff JC, Christian PJ, Marion SL, Arrandale A, Hoyer PB. Characterization of cyclicity and hormonal profile with impending ovarian failure in a novel chemical-induced mouse model of perimenopause. Comput Med Imaging Graph 55: 523–527, 2005.
  13. Lohff JC, Christian PJ, Marion SL, Hoyer PB. Effect of duration of dosing on onset of ovarian failure in a chemical-induced mouse model of perimenopause. Menopause 13: 482–488, 2006.[CrossRef][ISI][Medline]
  14. Maeda M, Yabuki A, Suzuki S, Matsumoto M, Taniguchi K, Nishinakagawa H. Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: acute phase of diabetes. Vet Pathol 40: 187–195, 2003.[Abstract/Free Full Text]
  15. Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 288: F399–F405, 2005.[Abstract/Free Full Text]
  16. Mankhey RW, Wells CC, Bhatti F, Maric C. 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol In press.
  17. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47: 1175–1187, 2004.[ISI][Medline]
  18. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging dahl salt sensitive rat. J Am Soc Nephrol 15: 1546–1556, 2004.[Abstract/Free Full Text]
  19. Matthews KA, Santoro N, Lasley B, Chang Y, Crawford S, Pasternak RC, Sutton-Tyrrell K, Sowers M. Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases. J Clin Endocrinol Metab 91: 1789–1795, 2006.[Abstract/Free Full Text]
  20. Mayer LP, Devine PJ, Dyer CA, Hoyer PB. The follicle-deplete mouse ovary produces androgen. Biol Reprod 71: 130–138, 2004.[Abstract/Free Full Text]
  21. McReynolds MR, Taylor-Garcia KM, Greer KA, Hoying JB, Brooks HL. Renal medullary gene expression in aquaporin-1 null mice. Am J Physiol Renal Physiol 288: F315–F321, 2005.[Abstract/Free Full Text]
  22. Mulroney SE, Woda C, Johnson M, Pesce C. Gender differences in renal growth and function after uninephrectomy in adult rats. Kidney Int 56: 944–953, 1999.[CrossRef][ISI][Medline]
  23. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 11: 319–329, 2000.[Abstract/Free Full Text]
  24. Nyengaard JR, Flyvbjerg A, Rasch R. The impact of renal growth, regression and regrowth in experimental diabetes mellitus on number and size of proximal and distal tubular cells in the rat kidney. Diabetologia V36: 1126–1131, 1993.[CrossRef][ISI][Medline]
  25. Ouar Z, Sole E, Bens M, Rafestin-Oblin ME, Meseguer A, Vandewalle A. Pleiotropic effects of dihydrotestosterone in immortalized mouse proximal tubule cells. Kidney Int 53: 59–66, 1998.[CrossRef][ISI][Medline]
  26. Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol 160: 1877–1885, 2002.[Abstract/Free Full Text]
  27. Quinkler M, Johanssen S, Bumke-Vogt C, Oelkers W, Bahr V, Diederich S. Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney. Mol Cell Endocrinol 171: 21–24, 2001.[CrossRef][ISI][Medline]
  28. Reckelhoff JF, Yanes LL, Iliescu R, Fortepiani LA, Granger JP. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 289: F941–F948, 2005.[Abstract/Free Full Text]
  29. Riazi S, Maric C, Ecelbarger CA. 17beta Estradiol attenuates streptozotocin-induced diabetes and regulates the expression of renal sodium transporters. Kidney Int 69: 471–480, 2006.[CrossRef][ISI][Medline]
  30. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365–386, 2000.[Medline]
  31. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 81: 1495–1501, 1996.[Abstract]
  32. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16: S30–S33, 2005.[Abstract/Free Full Text]
  33. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971–1010, 2004.[Abstract/Free Full Text]
  34. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 10: 219–225, 2001.[ISI][Medline]
  35. Susztak K, Bottinger E, Novetsky A, Liang D, Zhu Y, Ciccone E, Wu D, Dunn S, McCue P, Sharma K. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53: 784–794, 2004.[Abstract/Free Full Text]
  36. Ushiroyama T, Sugimoto O. Endocrine function of the peri- and postmenopausal ovary. Horm Res 44: 64–68, 1995.[ISI][Medline]
  37. Williams JK. A mouse model of the perimenopausal transition: importance for cardiovascular research. Arterioscler Thromb Vasc Biol 25: 1765–1766, 2005.[Free Full Text]
  38. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393–405, 1999.[CrossRef][ISI][Medline]
  39. Zeng XR, Jiang Y, Zhang SJ, Hao H, Lee MY. DNA polymerase delta is involved in the cellular response to UV damage in human cells. J Biol Chem 269: 13748–13751, 1994.[Abstract/Free Full Text]
  40. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93: 536–542, 1994.[ISI][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Table
Right arrow All Versions of this Article:
293/1/F193    most recent
00022.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keck, M.
Right arrow Articles by Brooks, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keck, M.
Right arrow Articles by Brooks, H. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.